USANA Health Sciences, Inc. USNA
- Market cap
- $263.5M
- P/E
- 0.0×
Follow USNA
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.00 | 52.55 | 69.55 | 58.30 | 43.01 | 77.06 | 48.61 | 44.01 | 31.44 | 18.48 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 75.00 | 76.15 | 137.95 | 119.37 | 92.26 | 107.85 | 103.26 | 69.60 | 54.81 | 38.32 |
High Price
|
|||
| 1,788 | 1,810 | 1,911 | 1,909 | 1,943 | 1,978 | 1,900 | 1,800 | 1,700 | 1,570 |
Employees
|
|||
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 1,006 | 1,047 | 1,189 | 1,061 | 1,135 | 1,186 | 999 | 921 | 855 | 925 |
Revenue
|
|||
| 82.09% | 82.87% | 83.12% | 82.33% | 81.57% | 81.63% | 80.58% | 80.82% | 81.13% | 78.29% |
Gross Margin
|
|||
| 139 | 135 | 192 | 150 | 178 | 171 | 109 | 102 | 76 | 42 |
EBT
|
|||
| 13.77% | 12.86% | 16.10% | 14.19% | 15.68% | 14.38% | 10.88% | 11.12% | 8.94% | 4.49% |
EBT Margin
|
|||
| 100 | 63 | 126 | 101 | 125 | 117 | 69 | 64 | 42 | 11 |
Net Income
|
|||
| 13 | 16 | 17 | 23 | 23 | 22 | 21 | 20 | 22 | 40 |
Depreciation
|
|||
| 41.60 | 43.01 | 49.34 | 46.85 | 53.63 | 58.89 | 51.86 | 47.84 | 44.73 | 49.92 |
Revenue/Sh
|
|||
| 3.99 | 2.53 | 5.12 | 4.41 | 5.86 | 5.73 | 3.59 | 3.30 | 2.19 | 0.58 |
Earnings/Sh
|
|||
| 5.66 | 5.08 | 6.31 | 5.60 | 7.58 | 6.02 | 5.40 | 3.67 | 3.19 | 1.21 |
Cash Flow/Sh
|
|||
| (1.35) | (0.54) | (0.46) | (0.73) | (0.71) | (0.63) | (0.54) | (0.75) | (0.52) | (0.54) |
Capex/Sh
|
|||
| 4.31 | 4.54 | 5.85 | 4.87 | 6.87 | 5.38 | 4.86 | 2.92 | 2.67 | 0.67 |
Free CF/Sh
|
|||
| 13.45 | 14.92 | 16.23 | 15.53 | 20.88 | 19.61 | 22.57 | 25.83 | 27.85 | 28.76 |
Book Value/Sh
|
|||
| 24 | 24 | 24 | 23 | 21 | 20 | 19 | 19 | 19 | 19 |
Shares
|
|||
| 16.13 | 29.74 | 23.04 | 17.77 | 13.16 | 17.72 | 15.17 | 16.50 | 16.31 | 35.69 |
PE Ratio
|
|||
| 1.50 | 1.74 | 2.39 | 1.68 | 1.44 | 1.72 | 1.05 | 1.14 | 0.80 | 0.39 |
PS Ratio
|
|||
| 4.62 | 5.02 | 7.26 | 5.06 | 3.69 | 5.16 | 2.41 | 2.11 | 1.29 | 0.68 |
PB Ratio
|
|||
| 1.39 | 1.57 | 2.21 | 1.47 | 1.17 | 1.52 | 0.77 | 0.79 | 0.60 | 0.23 |
EV/Sales
|
|||
| 13.38 | 14.87 | 18.62 | 14.17 | 9.17 | 16.68 | 8.20 | 12.90 | 10.02 | 17.08 |
EV/FCF
|
|||
| 137 | 124 | 152 | 127 | 160 | 121 | 104 | 71 | 61 | 22 |
Op' Cash Flow
|
|||
| (33) | (13) | (11) | (17) | (15) | (13) | (10) | (14) | (10) | (10) |
Capex
|
|||
| 104 | 111 | 141 | 110 | 145 | 108 | 94 | 56 | 51 | 12 |
FCF
|
|||
| 139 | 199 | 244 | 193 | 257 | 204 | 241 | 299 | 140 | 160 |
Working Cap'
|
|||
| — | — | — | 26 | 21 | 17 | 14 | — | — | — |
Total Debt
|
|||
| (176) | (247) | (278) | (235) | (312) | (240) | (288) | (330) | (182) | (158) |
Net Debt
|
|||
| 325 | 363 | 391 | 352 | 442 | 395 | 434 | 497 | 532 | 533 |
Sh' Equity
|
|||
| 22.38% | 12.63% | 23.51% | 18.77% | 21.53% | 19.12% | 11.81% | 10.38% | 6.09% | 1.44% |
ROA
|
|||
| 57.95% | 71.34% | 103.92% | 78.17% | 85.03% | 68.50% | 46.05% | 34.88% | 11.83% | 6.24% |
ROIC
|
|||
| 33.01% | 18.17% | 33.47% | 27.06% | 31.43% | 27.85% | 16.72% | 13.69% | 8.17% | 2.02% |
ROE
|
|||
USANA Health Sciences, Inc. (USNA) key facts
- USANA Health Sciences, Inc. (USNA) is a Packaged Foods company in the Consumer Defensive sector, listed on the New York Stock Exchange.
- USANA Health Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $925.3 million, up 8.28% from fiscal 2024.
- Net income was $11.5 million, or $0.58 per share (basic), a net margin of 1.16%.
- As of September 25, 2026, USNA traded at $14.57, a market capitalization of $263.5 million.
- Return on equity was 2.02% and debt-to-equity 0.00.
USANA Health Sciences, Inc. (USNA) Latest News
31 Aug
USANA Health Sciences Q2 earnings reviewed in personal care stocks sector, detailing financial results and positioning relative to peers. Q2 earnings data directly informs financial performance and investor views on operations.
12 Aug
USANA Health Sciences held a Q2 earnings call where analysts asked about sales trends, product strategies, international growth, cost management and competitive pressures. Earnings call details can shape near-term investor views on USANA operations and outlook.
11 Aug
USANA Health Sciences, Inc. (USNA) held its Q2 2026 earnings call, covering financial results and operational updates. Earnings releases typically provide performance data that can shift near-term investor views without altering long-term strategy.
9 Aug
USANA Health Sciences Q2 earnings call highlighted financial results, operational updates, and forward guidance for the company. Q2 earnings data and guidance directly shape near-term stock valuation and investor outlook.
6 Aug
USANA Health Sciences reported a Q2 loss and lowered full-year guidance, raising questions on whether its valuation should be revisited. Lowered guidance combined with a quarterly loss signals materially weaker financial outlook likely to pressure USNA stock and investor sentiment.
5 Aug
USANA Health Sciences Inc (USNA) reported Q2 2026 earnings call highlights focused on strategic pivots amid market conditions. Strategic pivots outlined in earnings call signal major operational shifts that can significantly alter company trajectory and investor views.
4 Aug
USANA missed Q2 CY2026 sales expectations, triggering a 19.2% stock drop. Missing quarterly sales targets and sharp stock decline point to notable pressure on near-term financial results and investor outlook.
USANA Health Sciences reported its second quarter 2026 results. Quarterly earnings directly shape near-term stock movement and investor views on operations.
14 Jul
USANA Health Sciences reported Q1 earnings that positioned the company as a top performer in the personal care sector. Strong Q1 earnings results can moderately lift near-term sentiment and valuation without altering long-term trajectory.
15 May
Analysts raised five revealing questions during USANA Health Sciences' Q1 earnings call, probing key aspects of performance, growth, and strategy. Revealing analyst questions from Q1 earnings call highlight potential concerns in financials and operations, exerting moderate influence on market sentiment and performance.
8 May
USANA Health Sciences, Inc. recorded a 78% earnings per share beat. Analysts now forecast future performance. A 78% EPS beat represents a significant positive earnings surprise likely to enhance investor sentiment and influence market performance.
6 May
USANA Health Sciences, Inc. (USNA) released Q1 2026 earnings call transcript detailing first-quarter financial results, management discussion, and forward guidance. Q1 2026 earnings transcript discloses financial metrics, operational updates, and future outlook directly influencing USNA's valuation and investor sentiment.
USANA Health Sciences, Inc. Q1 2026 earnings call summary covers quarterly financial results, sales performance, and management outlook. Q1 2026 earnings details impact financial performance and investor sentiment moderately.
5 May
USANA (NYSE:USNA) delivered impressive Q1 CY2026 results. Impressive quarterly earnings indicate strong financial performance with potential to significantly enhance market position and investor sentiment.
USANA Health Sciences reported first quarter 2026 results, detailing financial performance amid ongoing operations. Quarterly earnings disclosures significantly shape investor sentiment and stock trajectory.
USANA Health Sciences (USNA) Q1 earnings and revenues surpassed analyst estimates. Q1 earnings and revenues beating estimates signals stronger financial performance with moderate positive influence on market sentiment and trajectory.
4 May
Analysts outline expectations for USANA Health Sciences' Q1 earnings, projecting revenue growth, EPS, margins, and key drivers amid competitive pressures in direct selling and nutrition supplements. Q1 earnings preview influences near-term financial expectations and stock sentiment without altering long-term strategy.
27 Apr
Q4 rundown compares USANA Health Sciences (NYSE:USNA) performance against other personal care stocks. Q4 performance comparison to personal care peers moderately affects competitive positioning and market sentiment.
16 Mar
EHC stock's valuation and expansion trends are analyzed to assess if they support a hold strategy for USANA Health Sciences, Inc. Valuation review and expansion trends moderately influence investor sentiment and stock holding decisions.
10 Mar
USANA Health Sciences (USNA) stock rose after Q4 loss narrowed more than expected and revenues increased year-over-year. Narrower-than-expected Q4 loss and year-over-year revenue growth positively affect financial performance and short-term market sentiment.
2 Mar
USANA Health Sciences (USNA) Q4 earnings spark debate on whether to buy, sell, or hold the stock, analyzing financial results, growth prospects, and market position. Q4 earnings directly impact financial performance, valuation, and investor decisions, potentially altering stock trajectory.
25 Feb
USANA Health Sciences launches Protein Pop Plus, an enhanced version of its popular Protein Pop snack, at Costco warehouses nationwide, expanding retail distribution and accessibility. Nationwide rollout at Costco boosts USANA's retail presence, sales potential, and market visibility significantly.
24 Feb
USANA Health Sciences' Q4 earnings call highlighted top 5 analyst questions on sales declines, margin pressures, China market challenges, product innovation, and 2024 guidance. Top analyst questions expose moderate concerns over sales, margins, and regional performance that may noticeably influence near-term investor sentiment and financial outlook.
19 Feb
USANA Health Sciences Q4 earnings call highlights financial results, growth metrics, and strategic outlook. Q4 earnings call highlights reveal quarterly financial performance and future guidance, significantly influencing investor sentiment and stock trajectory.
18 Feb
USANA Health Sciences Inc (USNA) Q4 2025 earnings call highlights strong EPS guidance and positive developments. Strong EPS guidance signals major positive shift in financial outlook and investor sentiment.
USANA Health Sciences, Inc. released Q4 2025 earnings call summary detailing financial results, sales performance, and future outlook. Q4 earnings call summary reveals financial metrics and guidance that significantly shape investor perceptions and company valuation.
USANA Health Sciences reported Q3 2024 net sales of $200.3 million, down 9% year-over-year, with adjusted EPS of $0.51 missing Wall Street estimates amid ongoing challenges in Greater China and other Asia Pacific markets; shares plunged 15% today. Earnings miss and regional sales weakness will moderately impact financial performance and investor sentiment but are part of ongoing trends.
17 Feb
USANA Health Sciences announced fourth quarter and full-year 2025 financial results, along with fiscal year 2026 outlook. Quarterly earnings results and forward outlook directly impact financial performance metrics and investor expectations.
USANA Health Sciences (USNA) Q4 earnings and revenues beat estimates. Q4 earnings and revenue beats indicate solid financial performance with moderately positive influence on market sentiment and near-term trajectory.
USANA Health Sciences reported Q4 earnings with revenue and EPS figures, alongside full-year results. Q4 earnings snapshot details financial performance, influencing investor sentiment and short-term stock trajectory.